An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors (CLOVER-2)

Administered By

Awarded By

Contributors

Start/End

  • December 29, 2021 - December 31, 2023